# Cancer Hematopoiesis and Immunology (CHI)

> **NIH NIH P30** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $77,090

## Abstract

PROJECT SUMMARY/ABSTRACT (CANCER HEMATOPOIESIS AND IMMUNOLOGY)
The mission of University of Michigan Rogel Cancer Center Cancer Hematopoiesis and Immunology (CHI)
Program is to generate new insights into the nature and biology of immunity and hematopoiesis during
homoeostasis and in the settings of cancer and hematopoietic cell transplantation (HCT). The CHI program’s
overarching goals are to delineate molecular mechanisms regulating immune/hematopoietic cells, their
interactions with the microenvironment, and the development of therapeutic strategies that can be translated in
an inter-programmatic manner. The CHI Program has $18.1M in annual direct funding (69% peer-reviewed),
with $4.4M from the NCI and $7.9M from other NIH sources. During the past project period, the Program
generated 624 publications, including high impact reports appearing in Cell, Nature, Science, NEJM, Nature
Immunology and the JCI. The CHI Program enjoys strong interactions with other Rogel members, underlined
by 18.1% of their publications arising from intra-programmatic efforts and 33.1% from inter-programmatic
collaborations. CHI members are highly engaged and have made major advancements in clinical research.
During the project period, CHI members enrolled 835 patients, over 23% to therapeutic interventional clinical
trials and 108 to non-treatment interventional trials. Of the 835 patients in therapeutic trials, 30% were in
institutional trials and 13% were enrolled in National Clinical Trials Network trials. To build on these advances,
Program aims include: 1) Elucidate the mechanisms regulating immune and non-immune hematopoietic cell
function during homeostasis, cancer progression, and cellular therapy; 2) Understand the mechanisms of
cross-talk between immune cells and non-immune cells in cancer therapy and HCT; and 3) Define key
concepts, approaches, and reagents in preclinical studies to translate selected advances into the clinic to
improve cancer outcomes and quality of life for patients and survivors. The CHI program is aligned with two
Rogel strategic research priorities: i) Cancer initiation, progression, and resistance; and ii) Cancer treatment
and care delivery paradigms. Program goals include exploration of molecular mechanisms regulating
immune/hematopoietic cells and their interactions with the microenvironment, and the development of new
treatment strategies via intra- and inter-programmatic translational collaborations. CHI member research
interests are relevant to six of the nine Rogel cross-cutting research themes: Tumor Microenvironment and
Metabolism; Molecular Determinants; Inflammation, Microbes and Immunity; Biomarkers; Health Equity; and
Targets and Therapeutics.

## Key facts

- **NIH application ID:** 10875451
- **Project number:** 5P30CA046592-35
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** WEIPING ZOU
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $77,090
- **Award type:** 5
- **Project period:** 1997-06-01 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10875451

## Citation

> US National Institutes of Health, RePORTER application 10875451, Cancer Hematopoiesis and Immunology (CHI) (5P30CA046592-35). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10875451. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*